Table 3 Summary of findings by secondary outcomes
Variable | N | Effect Size (95% CI) | Heterogeneity (I2) |
|---|---|---|---|
Analgesic consumption at 0-8 h | |||
 remifentanil vs placebo | 306 | SMD 0.42(0.09, 0.75) | 51% |
 high dose vs low dose | 675 | SMD 1.28(0.41,2.16) | 96% |
Analgesic consumption at 12 h | |||
 high dose vs low dose | 557 | SMD 2.50(1.17,3.83) | 98% |
Analgesic consumption at 24-48 h | |||
 remifentanil vs placebo | 446 | SMD 0.08(-0.31, 0.47) | 75% |
 high dose vs low dose | 1041 | SMD 0.94 (0.40, 1.49) | 94% |
Time to first postoperative analgesic requirement | |||
 remifentanil vs placebo | 200 | WMD -25.27(-32.09, -18.46) | 72% |
 high dose vs low dose | 521 | WMD -7.53(-10.31, -4.75) | 31% |
PONV | |||
 remifentanil vs placebo | 414 | OR 1.46(0.92, 2.32) | 0% |
 high dose vs low dose | 1231 | OR 1.13(0.87, 1.45) | 9% |